Recombinant Brucella melitensis biotype 1 Large-conductance mechanosensitive channel (mscL)

What are the differences between B. melitensis biotype 1 and biotype 2 mscL proteins?

Comparative analysis of B. melitensis biotype 1 and biotype 2 mscL proteins reveals identical amino acid sequences (138 amino acids) and similar structural properties . This conservation is notable considering the differences observed in other proteins between these biotypes.

Despite their identical sequences, these proteins have different UniProt IDs:

• Biotype 1: Q8YFB7 (BMEI1605)

• Biotype 2: C0RH35 (BMEA_A0356)

The genomic context may differ slightly between biotypes, though the functional significance of these differences has not been extensively characterized in the literature .

What expression systems are used for recombinant B. melitensis mscL production?

The most commonly employed expression system for recombinant B. melitensis mscL is Escherichia coli, specifically strains optimized for protein expression such as BL21(DE3) . The general methodology involves:

• Amplification of the mscL gene from B. melitensis genomic DNA

• Cloning into expression vectors (commonly pET-based systems with His-tag for purification)

• Transformation into E. coli expression hosts

• Induction of protein expression (typically with IPTG)

• Cell lysis and protein purification using affinity chromatography

While E. coli is most common, studies comparing different expression systems have found that Pichia pastoris may offer advantages for certain Brucella proteins, providing higher expression levels and potentially better immunogenicity for some recombinant antigens .

What purification strategies yield optimal results for recombinant B. melitensis mscL?

Based on the available literature, the following purification strategy has proven effective for recombinant B. melitensis mscL :

• Expression with affinity tag: N-terminal His-tag fusion facilitates one-step purification

• Cell lysis: Typically using sonication or commercial lysis buffers in the presence of protease inhibitors

• Affinity purification: Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin

• Buffer formulation: Final storage in Tris/PBS-based buffer with 6% trehalose, pH 8.0

• Storage stabilization: Addition of 50% glycerol for long-term storage at -20°C/-80°C

Researchers should pay particular attention to protein solubility, as membrane proteins like mscL may form inclusion bodies. Optimization of induction conditions (temperature, IPTG concentration, duration) is critical for maximizing soluble protein yield .

How can protein stability of recombinant mscL be maintained during storage?

Maintaining stability of recombinant mscL requires attention to several factors:

• Buffer composition: Tris/PBS-based buffers with pH 8.0 have been reported as optimal

• Cryoprotectants: Addition of 6% trehalose helps maintain protein structure during freeze-thaw cycles

• Storage recommendations:

  • Lyophilized form: 12 months at -20°C/-80°C

  • Liquid form: 6 months at -20°C/-80°C

  • Working aliquots: Up to one week at 4°C

• Aliquoting: Dividing into single-use aliquots is essential as repeated freeze-thaw cycles significantly reduce protein activity

• Reconstitution: For lyophilized protein, reconstitution in deionized sterile water to 0.1-1.0 mg/mL is recommended

Studies have shown that adding glycerol to a final concentration of 50% significantly extends shelf life during storage at -20°C/-80°C .

How can recombinant mscL be incorporated into multi-subunit vaccine strategies against brucellosis?

Research on subunit vaccines against brucellosis suggests that combining multiple recombinant proteins often provides superior protection compared to single-antigen approaches . When considering mscL for inclusion in such vaccines:

• Antigen combination strategy: Studies with other Brucella proteins have shown that combining outer membrane proteins (Omps) with ribosomal proteins yields enhanced immune responses. For example, a combination of Omp10, Omp28, and L7/L12 demonstrated significant protective efficacy .

• Adjuvant selection: The addition of appropriate adjuvants significantly enhances protective efficacy. Research on Omp-based vaccines found that TPPPS (Taishan Pinus massoniana pollen polysaccharide) significantly improved protective effects of subunit vaccines against B. melitensis challenge .

• Expression system impact: The choice of expression system affects immunogenicity. For instance, the Omp10-Omp28-L7/L12 recombinant protein expressed in Pichia pastoris exhibited slightly higher immunogenicity than the same protein expressed in E. coli .

• Immune response profiling: Effective vaccine candidates should induce both humoral and cell-mediated immunity. In mouse models, successful subunit vaccines elicited:

  • Increased CD4+ and CD8+ T lymphocytes

  • Enhanced production of IFN-γ and IL-2 (Th1 cytokines)

  • Balanced IgG2a/IgG1 antibody responses

While mscL has not been specifically tested in multi-subunit vaccine formulations, its conservation and surface exposure make it a candidate worth investigating in combination with established immunogens such as Omp28, L7/L12, and VirB proteins.

How do experimental approaches for studying mscL function differ between biotypes of B. melitensis?

Studying mscL function across different B. melitensis biotypes requires carefully designed experimental approaches to account for biotype-specific characteristics:

• Genomic considerations: While the mscL protein sequence is identical between biotypes 1 and 2, genomic context differences necessitate biotype-specific primer design for gene amplification. Studies have shown that biotyping through PCR-RFLP methods can distinguish biotypes reliably .

• Strain selection: For biotype 1, strain 16M (ATCC 23456) is the reference strain, while for biotype 2, strain ATCC 23457 is commonly used . The choice of reference strain affects experimental standardization and comparative analyses.

• Virulence correlation: Biotype distribution varies geographically, with studies showing different prevalence patterns. For example, one study in Saudi Arabia found that 41% of isolates were biovar 1, 56% biovar 2, and 2% biovar 3 . These distribution patterns may correlate with different virulence profiles that affect mscL function studies.

• Transcriptomic analysis: Comparative transcriptome analysis between biotypes can reveal differential gene regulation patterns. Similar approaches comparing virulent and attenuated strains have identified differentially expressed genes that contribute to pathogenesis .

• Protein-protein interaction networks: Biotype-specific protein interaction networks may affect mscL function and should be considered when designing experiments to study channel activity and regulation.

What structural and functional comparisons can be made between B. melitensis mscL and homologs in other bacterial species?

Comparative analysis of B. melitensis mscL with homologs in other bacterial species reveals important structural and functional insights:

Functional differences between these homologs include:

• Channel gating mechanisms: The hydrophobic constriction that forms the gate may have species-specific amino acid compositions

• Pressure sensitivity thresholds: Different homologs activate at different membrane tension thresholds

• Ion selectivity: While primarily mechanosensitive, subtle differences in pore structure may affect ion preference

• Regulatory mechanisms: Interactions with other membrane components may differ between species

Understanding these differences is crucial for leveraging structural information from better-characterized homologs (like E. coli MscL) when studying the B. melitensis protein . Crystal structure analysis of MscL from M. tuberculosis at 3.5 Å resolution revealed a homopentameric channel that undergoes extensive rearrangement during opening, which likely applies to the B. melitensis homolog as well .